These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6160633)

  • 1. On the interaction between dextran and the primary fibrinolysis inhibitor alpha 2-antiplasmin.
    Carlin G; Saldeen T
    Thromb Res; 1980 Jul 1-15; 19(1-2):103-10. PubMed ID: 6160633
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of dextran sulfate and tranexamic acid on the activation of plasminogen by urokinase.
    Takada Y; Takada A
    Thromb Res; 1979; 16(5-6):865-9. PubMed ID: 160629
    [No Abstract]   [Full Text] [Related]  

  • 3. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 4. Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid.
    Takada A; Takada Y
    Thromb Res; 1980 Apr 1-15; 18(1-2):237-46. PubMed ID: 6157220
    [No Abstract]   [Full Text] [Related]  

  • 5. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
    Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
    Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of alpha 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage.
    Hayashi S; Yamada K
    Thromb Res; 1979; 16(3-4):393-400. PubMed ID: 92817
    [No Abstract]   [Full Text] [Related]  

  • 8. [Streptokinase or urokinase: the elements of choice].
    Pâques EP
    Haemostasis; 1986; 16 Suppl 4():21-5. PubMed ID: 2429902
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1990 Feb; 87(3):1114-8. PubMed ID: 1689060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
    Sakai M; Watanuki M; Matsuo O
    Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit.
    Voss R; Matthias FR; Borkowski G; Reitz D
    Br J Haematol; 1990 May; 75(1):99-105. PubMed ID: 1695855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 17. [In vitro study of a human plasmin (CY 218) and its association with urokinase (author's transl)].
    Brochier M; Griguer P
    Rev Med Brux; 1981 Mar; 2(3):167-74. PubMed ID: 6453415
    [No Abstract]   [Full Text] [Related]  

  • 18. [Molecular mechanisms of thrombolytic therapy].
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings: Influence of plasmin inhibitors on differentiating digestion between fibrinogenolysis and fibrinolysis.
    Abe T; Kazama M
    Thromb Diath Haemorrh; 1975 Nov; 34(2):584. PubMed ID: 53895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.